Last update Aug. 22, 2022
Very Low Risk
We do not have alternatives for Fil: L03AA02. ; Pegfil: L03AA13 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Fil: L03AA02. ; Pegfil: L03AA13 is Filgrastim in ATC Code/s.Is written in other languages:
Fil: L03AA02. ; Pegfil: L03AA13 is also known as
Fil: L03AA02. ; Pegfil: L03AA13 belongs to this group or family:
Main tradenames from several countries containing Fil: L03AA02. ; Pegfil: L03AA13 in its composition:
|Oral Bioavail.||≈ 0||%|
|Molecular weight||Fil: 18.800 ; Pegfil: 39.000||daltons|
|VD||Fil: 0.15 ; Pegfil: 2.4||l/Kg|
|Tmax||Fil: 2 - 8 ; Pegfil: 24 - 48||hours|
|T½||Fil: 3.5 ; Pegfil: 42||hours|
|Theoretical Dose||0.000028 - 0.00009||mg/Kg/d|
|Relative Dose||0.13 - 0.56||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Filgrastim is a non-glycosylated stimulating factor of granulocyte colonies (G-CSF) which is obtained by recombinant technology. The naturally occurring product is found in breast milk. Pegfilgrastim and Lipegfilgrastim are Filgrastim conjugated with monomethoxy polyethylene glycol (PEG). They are used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Intravenous or subcutaneous administration.
A very high molecular weight explains the insignificant or no excretion into milk that has been observed both with Lenograstim and Filgrastim. (Nelson 2018, Kaida 2007, Shibata 2003)
Its low oral bioavailability hampers absorption into infant plasma from the breast milk ingested, as for their proteic nature it is degraded in the gastrointestinal tract, not being absorbed. Filgrastim is not absorbed by the infant's gut even during the neonatal period or prematurity. (Calhoun 2003)
The granulocyte colony-stimulating factor has been used in premature newborns, both on prevention and treatment of neonatal sepsis and/or necrotizing enterocolitis without adverse effects being observed among treated infants. (Canpolat 2006, Carr 2003, Bedford 2001, Gillan 1994))
Granulocyte colony-stimulating factor (G-CSF) is a normal component of breastmilk. The bovine G-CSF is found in the usual diet of meat eaters. (Pessach 2013)
Expert authors consider the use of this medication to be safe or very probably safe during breastfeeding. (LactMed, Briggs 2015, Pistilli 2013)